Belgian real-world data confirm the potential of benralizumab to induce clinical remission in patients with severe eosinophilic asthma - Vienna 2024

Biological treatments for asthma: novel real-world and clinical studies

Chair(s): Madeleine R?dinger, Lena Uller

Session type: Poster session

Belgian real-world data confirm the potential of benralizumab to induce clinical remission in patients with severe eosinophilic asthma

Tom Feys

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium.

Guillermo Bentabol Ramos

Poster

Abstract

Clinical remission by BMI in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab: real-world XALOC-2 programme

Marek Lommatzsch

Poster

Abstract

Late Breaking Abstract - A phase 1 study of subcutaneous administration of ARO-RAGE

Mark O'carroll

Poster

Abstract

Late Breaking Abstract - The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD

Dave Singh

Poster

Abstract

Real-world effectiveness of switching to Benralizumab in patients with severe asthma in the Catalan population. Catalan Society of Pulmonology (SOCAP) Registry.

Ebymar Arismendi

Poster

Abstract

Efficacy of switching controlled and uncontrolled asthma patients on Mepolizumab to Benralizumab

Riyad Allehebi

Poster

Abstract

Real-life effectiveness of benralizumab in severe asthma: 12-month data from the RAMSES cohort in France

Camille Taill

Poster

Abstract

Effectiveness of mepolizumab on severe asthma in Argentina: a real-world cohort study

Federico Daniel Colodenco

Poster

Abstract

Long-term effectiveness and safety of dupilumab in severe asthma: a 5-year real-life multicenter observational cohort study

Clairelyne Dupin

Abstract

The REALISM Study: The Experience of Pulmonologists with Benralizumab in Greece

Chrysoula Kontogianni

Poster

Abstract

Decreased Number of Uncontrolled Severe Asthma Patients while Need of OCS Reduction Remains: RWE Data Analysis in Germany 2022 vs 2019

Athanasios Xanthopoulos

Poster

Abstract

Covid 19 emerging as etiology for novel phenotype of Asthma

Abhisheka Kumar

Abstract

Real-world effectiveness of mepolizumab in patients with severe asthma with/without chronic rhinosinusitis with nasal polyps: pooled analysis from European cohorts

Ines Palomares

Poster

Abstract

Belgian real-world data confirm the potential of benralizumab to induce clinical remission in patients with severe eosinophilic asthma

Tom Feys

Poster

Abstract

Evolution of Blood Eosinophilia in Patients with Severe Asthma Treated with Dupilumab

Cristina Bellver

Poster

Abstract

A Belgian real-world study indicates rapid and sustained asthma symptom control with benralizumab

Tom Feys

Poster

Abstract

Effects of benralizumab on inspiratory capacity evaluated during exercise in severe asthmatics

Lorena Gentile

Poster

Abstract

Characteristics of never-, switching, and persisting users of biologics for severe asthma a SHARP-CRC study

Kjell E J H?kansson

Poster

Abstract

Early treatment response to dupilumab on airway inflammation, airway dynamics, and mucus plugging in VESTIGE

Alberto Papi

Poster

Abstract

Late Breaking Abstract - Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia

Manali Mukherjee

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}